

# Valeria Visconte

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3828841/valeria-visconte-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100  
papers

1,608  
citations

17  
h-index

39  
g-index

106  
ext. papers

1,993  
ext. citations

4.6  
avg, IF

4.33  
L-index

#	Paper	IF	Citations
100	Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. <i>Blood</i> , <b>2012</b> , 119, 3203-10	2.2	293
99	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. <i>Leukemia</i> , <b>2014</b> , 28, 78-87	10.7	226
98	SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. <i>Leukemia</i> , <b>2012</b> , 26, 542-5	10.7	178
97	SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. <i>Blood</i> , <b>2012</b> , 120, 3173-86	2.2	152
96	Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. <i>Leukemia</i> , <b>2012</b> , 26, 2447-54	10.7	82
95	Genomic determinants of chronic myelomonocytic leukemia. <i>Leukemia</i> , <b>2017</b> , 31, 2815-2823	10.7	61
94	Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. <i>Cell Reports</i> , <b>2014</b> , 9, 1333-48	10.6	41
93	Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. <i>Leukemia</i> , <b>2018</b> , 32, 230-233	10.7	39
92	Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. <i>Leukemia Research</i> , <b>2014</b> , 38, 1245-51	2.7	38
91	Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. <i>Blood Research</i> , <b>2014</b> , 49, 216-27	1.4	38
90	Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron. <i>Leukemia</i> , <b>2015</b> , 29, 188-95	10.7	37
89	Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. <i>Leukemia</i> , <b>2014</b> , 28, 1486-93	10.7	37
88	Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features. <i>Cancers</i> , <b>2019</b> , 11,	6.6	33
87	Consequences of mutant TET2 on clonality and subclonal hierarchy. <i>Leukemia</i> , <b>2018</b> , 32, 1751-1761	10.7	30
86	Rational management approach to pure red cell aplasia. <i>Haematologica</i> , <b>2018</b> , 103, 221-230	6.6	29
85	Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms. <i>Leukemia</i> , <b>2017</b> , 31, 505-510	10.7	19
84	Invariant phenotype and molecular association of biallelic mutant myeloid neoplasia. <i>Blood Advances</i> , <b>2019</b> , 3, 339-349	7.8	18

83	Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine. <i>Leukemia</i> , <b>2016</b> , 30, 1190-4	10.7	16
82	Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. <i>Journal of Hematology and Oncology</i> , <b>2014</b> , 7, 89	22.4	16
81	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. <i>Leukemia</i> , <b>2020</b> , 34, 957-962	10.7	16
80	Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity. <i>Blood Advances</i> , <b>2019</b> , 3, 1318-1329	7.8	14
79	Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. <i>Communications Biology</i> , <b>2020</b> , 3, 493	6.7	13
78	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. <i>Blood</i> , <b>2021</b> , 137, 3685-3689		12
77	Distinct clinical and biological implications of in myeloid neoplasms. <i>Blood Advances</i> , <b>2019</b> , 3, 2164-2178	7.8	12
76	SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype. <i>Haematologica</i> , <b>2013</b> , 98, e105-7	6.6	11
75	Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	11
74	Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 406-9	7.1	11
73	Molecular pathogenesis of myelodysplastic syndromes. <i>Translational Medicine @ UniSa</i> , <b>2014</b> , 8, 19-30	0.5	10
72	Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms. <i>Leukemia</i> , <b>2018</b> , 32, 550-553	10.7	9
71	Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10). <i>American Journal of Hematology</i> , <b>2014</b> , 89, 862	7.1	9
70	Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34). <i>International Journal of Laboratory Hematology</i> , <b>2017</b> , 39, 409-417	2.5	8
69	Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. <i>British Journal of Haematology</i> , <b>2020</b> , 188, 924-929	4.5	8
68	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
67	Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 212-5	1.9	6
66	Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6

65	The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications. <i>Cells</i> , <b>2020</b> , 9,	7.9	5
64	Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 193-5	1.9	4
63	Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 489-95	2	4
62	Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 318-322	4.5	3
61	Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2014. <i>Leukemia Research</i> , <b>2015</b> , 39, 110-3	2.7	3
60	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. <i>Blood</i> , <b>2021</b> , 138, 1885-1895	2.2	3
59	Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. <i>Blood Cells, Molecules, and Diseases</i> , <b>2021</b> , 87, 102528	2.1	3
58	Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. <i>Leukemia</i> , <b>2021</b> , 35, 2431-2434	10.7	3
57	A case of mistaken identity: When lupus masquerades as primary myelofibrosis. <i>SAGE Open Medical Case Reports</i> , <b>2013</b> , 1, 2050313X13498709	0.7	2
56	TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia. <i>Blood</i> , <b>2019</b> , 134, 880-880	2.2	2
55	A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 3960-3960	2.2	2
54	Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes. <i>Blood</i> , <b>2016</b> , 128, 4301-4301	2.2	2
53	The Similarity of Class II HLA Genotypes Defines Patterns of Autoreactivity in Idiopathic Bone Marrow Failure Disorders. <i>Blood</i> , <b>2021</b> ,	2.2	2
52	Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 187	7	2
51	Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?. <i>Blood</i> , <b>2019</b> , 134, 1404-1404	2.2	2
50	Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	2
49	Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 735-738	1.9	2
48	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	2

47	Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts. <i>American Journal of Hematology</i> , <b>2016</b> , 91, E273-4	7.1	1
46	Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1888-90	1.9	1
45	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. <i>Blood</i> , <b>2019</b> , 134, 2696-2696	2.2	1
44	The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia. <i>Blood</i> , <b>2020</b> , 136, 8-8	2.2	1
43	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. <i>Blood</i> , <b>2020</b> , 136, 2-2	2.2	1
42	Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia. <i>Blood</i> , <b>2020</b> , 136, 1-1	2.2	1
41	Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2012</b> , 120, 1973-1973	2.2	1
40	Splicing Factor 3b Subunit 1 (SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 (SLC25A37). <i>Blood</i> , <b>2013</b> , 122, 1555-1555	2.2	1
39	We cannot paint them all with the same brush—the need for a better definition of patients with myelodysplastic syndromes for clinical trial design. <i>British Journal of Haematology</i> , <b>2021</b> , 196, 268	4.5	1
38	Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets. <i>Blood</i> , <b>2019</b> , 134, 1703-1703	2.2	1
37	The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
36	Leukemia evolving from paroxysmal nocturnal hemoglobinuria. <i>Leukemia</i> , <b>2020</b> , 34, 327-330	10.7	1
35	Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. <i>Blood Cells, Molecules, and Diseases</i> , <b>2021</b> , 91, 102595	2.1	1
34	Molecular and Clinical Aspects of Acute Myeloid Leukemia with Inv(3)(q21q26)/t(3;3)(q21;q26) Carrying Spliceosomal Mutations. <i>Blood</i> , <b>2020</b> , 136, 7-8	2.2	0
33	Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia.. <i>Seminars in Hematology</i> , <b>2022</b> , 59, 47-53	4	0
32	A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia.. <i>Hematological Oncology</i> , <b>2022</b> ,	1.3	0
31	TERT Rare Variants in Myeloid Neoplasia: Lack of Clinical Impact or Role as Risk Alleles. <i>Blood</i> , <b>2021</b> , 138, 1537-1537	2.2	0
30	Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML. <i>Blood</i> , <b>2015</b> , 126, 1350-1350	2.2	0

29	Friend or foe? The case of WilmsRTumor 1 (WT1) mutations in acute myeloid leukemia. <i>Blood Cells, Molecules, and Diseases</i> , <b>2021</b> , 88, 102549	2.1	○
28	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. <i>Leukemia</i> , <b>2021</b> , 35, 3324-3328	10.7	○
27	Cyclosporine dependent pure red cell aplasia: a case presentation. <i>Blood Cells, Molecules, and Diseases</i> , <b>2015</b> , 54, 281-3	2.1	
26	Co-Existence of Splicing Factor Mutations in Myeloid Malignancies. <i>Blood</i> , <b>2020</b> , 136, 33-34	2.2	
25	Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles. <i>Blood</i> , <b>2020</b> , 136, 25-25	2.2	
24	Immunogenomics of Paroxysmal Nocturnal Hemoglobinuria: A Model of Immune Escape. <i>Blood</i> , <b>2020</b> , 136, 21-22	2.2	
23	Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , <b>2020</b> , 136, 2-3	2.2	
22	Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms. <i>Blood</i> , <b>2020</b> , 136, 28-28	2.2	
21	The Genomic Landscape of WilmsRTumor 1 (WT1) Mutant Acute Myeloid Leukemia. <i>Blood</i> , <b>2020</b> , 136, 28-28	2.2	
20	Molecular and Expression Characterization of Monosomy 7 and Del(7q). <i>Blood</i> , <b>2020</b> , 136, 33-33	2.2	
19	Implication of Piga Genotype on Clinical Features of PNH. <i>Blood</i> , <b>2020</b> , 136, 34-35	2.2	
18	Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia. <i>Blood</i> , <b>2020</b> , 136, 34-35	2.2	
17	Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence. <i>Blood</i> , <b>2020</b> , 136, 20-21	2.2	
16	Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA. <i>Blood</i> , <b>2020</b> , 136, 2-3	2.2	
15	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. <i>Blood</i> , <b>2020</b> , 136, 21-21	2.2	
14	Genomic Landscape of Splicing Factor Mutant Acute Myeloid Leukemia. <i>Blood</i> , <b>2020</b> , 136, 36-36	2.2	
13	Comparative Genomic Analysis of Adolescents and Young Adults Versus Elderly with Acute Myeloid Leukemia. <i>Blood</i> , <b>2020</b> , 136, 18-18	2.2	
12	Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS. <i>Blood</i> , <b>2018</b> , 132, 3074-3074	2.2	

- 11 T-cell large granular lymphocytic leukemia evolution post-transplant: The Cleveland Clinic experience.. *Journal of Clinical Oncology*, **2019**, 37, e19072-e19072 2.2
- 10 CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q). *Blood*, **2019**, 134, 1281-1281.2
- 9 Predicting the Outcome in Egyptian Patients with Severe Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Matched Sibling Donors. *Blood*, **2019**, 134, 5652-5652 2.2
- 8 Molecular Characterization of EP300 Mutant Myeloid Neoplasia. *Blood*, **2019**, 134, 5043-5043 2.2
- 7 Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia. *Blood*, **2019**, 134, 3750-3750.2
- 6 Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation. *Blood*, **2019**, 134, 1226-1226 2.2
- 5 Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential. *Blood*, **2019**, 134, 3743-3743 2.2
- 4 Small Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Refractory Multiple Myeloma. *Blood*, **2015**, 126, 1807-1807 2.2
- 3 Acquired Molecular Defects in Spliceosome Machinery: Novel Pathogenetic Pathways in Myeloid Leukemogenesis. *Blood*, **2011**, 118, 271-271 2.2
- 2 Spliceosome Gene Mutations Are Frequently Found In JAK2 Negative Myelofibrosis and Associated With Worse Clinical Outcomes. *Blood*, **2013**, 122, 4063-4063 2.2
- 1 The first concurrent diagnosis of acute symptomatic Babesiosis and chronic myeloid leukemia in a healthy young adult. *Blood Research*, **2018**, 53, 163-166 1.4